vida: extract claims from 2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation

- Source: inbox/queue/2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Psychiatric pharmacotherapy shows the same benefit-reversion pattern as metabolic drugs but has a mitigation pathway through behavioral intervention that metabolic treatments lack
+confidence: likely
+source: The Lancet Psychiatry, network meta-analysis of 76 RCTs with 17,000+ adults
+created: 2026-04-11
+title: "Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication"
+agent: vida
+scope: causal
+sourcer: The Lancet Psychiatry
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Low-dose semaglutide demonstrates cardiac remodeling benefits independent of weight loss, suggesting therapeutic utility in non-obese or sarcopenia-vulnerable HFpEF patients
+confidence: experimental
+source: bioRxiv preprint, ZSF1 obese rat model with single-cell RNA sequencing
+created: 2026-04-11
+title: GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+agent: vida
+scope: causal
+sourcer: bioRxiv preprint
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+
+This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Direct GLP-1R cardiac effects (cardiomyocyte protection, anti-fibrotic, anti-inflammatory) are distinct from metabolic/weight effects, resolving the STEER counterintuitive finding
+confidence: experimental
+source: "Circulation: Heart Failure mechanistic review, STEER study comparative data"
+created: 2026-04-11
+title: GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+agent: vida
+scope: causal
+sourcer: "Circulation: Heart Failure (AHA Journals)"
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+
+GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macrophages, and improved renal sodium handling independent of weight changes. This mechanistic framework explains the STEER study finding where semaglutide showed 29-43% lower MACE than tirzepatide in matched ASCVD patients despite tirzepatide being superior for weight loss. The key distinction is that tirzepatide's GIPR agonism adds metabolic benefit but may not add cardiovascular benefit beyond GLP-1R effects alone. This suggests the GLP-1R-specific cardiac mechanism is the primary driver of cardiovascular benefit, not the weight loss itself. The therapeutic implication is that non-obese HFpEF patients may benefit from GLP-1RAs through these weight-independent mechanisms, and lower doses that minimize appetite suppression while preserving GLP-1R cardiac signaling might provide cardiovascular benefit while reducing sarcopenia risk from excessive lean mass loss.

inbox/archive/health/2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation.md

@@ -7,9 +7,12 @@ date: 2025-06-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: medium
 tags: [GLP-1, HFpEF, mechanism, weight-independent, cardiac, GLP-1R, GIPR, tirzepatide, semaglutide, STEER]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-xx-pubmed-glp1-micronutrient-nutritional-deficiencies-narrative-review.md

@@ -7,9 +7,12 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [GLP-1, micronutrient, deficiency, nutrition, vitamin-D, iron, calcium, protein, sarcopenia, monitoring, 2026]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content